Application of furazolidone in Helicobacter pylori infection eradication
- PMID: 38624062
- DOI: 10.1111/1751-2980.13265
Application of furazolidone in Helicobacter pylori infection eradication
Abstract
Increasing antibiotic resistance is the primary reason for treatment failure of Helicobacter pylori (H. pylori) infection. To enhance the eradication rate, minimize the development of secondary resistance, and alleviate the socioeconomic burden, it is crucial to select H. pylori-sensitive antibiotics carefully. Furazolidone has been used for H. pylori eradication in developing countries for decades due to its affordability and low resistance rate. Numerous studies have demonstrated that furazolidone-containing regimens are more efficacious than those containing other antibiotics, as both first- and second-line therapies, and are also well tolerated. However, utility of furazolidone is restricted or not optimal in certain countries due to its infrequent but potentially severe adverse effects. The decision to discontinue usage of furazolidone because of concerns regarding adverse effects may be misguided. Here we comprehensively reviewed the studies on furazolidone at different dosages and treatment durations for H. pylori eradication. Further research on the mechanisms of action and clinical trials of furazolidone are of great practical importance.
Keywords: Helicobacter pylori; eradication; furazolidone; safety.
© 2024 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Similar articles
-
Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.World J Gastroenterol. 2014 Aug 28;20(32):11415-21. doi: 10.3748/wjg.v20.i32.11415. World J Gastroenterol. 2014. PMID: 25170230 Free PMC article. Clinical Trial.
-
Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication.World J Gastroenterol. 2018 Oct 28;24(40):4596-4605. doi: 10.3748/wjg.v24.i40.4596. World J Gastroenterol. 2018. PMID: 30386109 Free PMC article.
-
Quadruple therapy with medications containing either rufloxacin or furazolidone as a rescue regimen in the treatment of Helicobacter pylori-infected dyspepsia patients: a randomized pilot study.Helicobacter. 2011 Aug;16(4):284-8. doi: 10.1111/j.1523-5378.2011.00848.x. Helicobacter. 2011. PMID: 21762267 Clinical Trial.
-
Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28529929 Free PMC article. Review.
-
Helicobacter pylori eradication in West Asia: a review.World J Gastroenterol. 2014 Aug 14;20(30):10355-67. doi: 10.3748/wjg.v20.i30.10355. World J Gastroenterol. 2014. PMID: 25132752 Free PMC article. Review.
Cited by
-
Efficacy and Safety of Modified Bismuth Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Microorganisms. 2025 Feb 26;13(3):519. doi: 10.3390/microorganisms13030519. Microorganisms. 2025. PMID: 40142411 Free PMC article. Review.
References
REFERENCES
-
- Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta‐analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553‐564.
-
- Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta‐analysis. Gastroenterology. 2017;153(2):420‐429.
-
- Malfertheiner P, Megraud F, O'Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6‐30.
-
- Tacconelli E, Carrara E, Savoldi A, et al; WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic‐resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318‐327.
-
- Gao HJ, Zhong ZS, Yan LJ, Zhang XY, Shen WX. Personalized therapy for Helicobacter pylori on initial treatment: the initial treatment is the decisive battle. Natl Med J China. 2022;102(22):1631‐1634. [in Chinese].
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical